Results 11 to 20 of about 2,367,876 (222)

CHRONIC MYELOMONOCYTIC LEUKEMIA

open access: yesHaematologica
Chronic myelomonocytic leukemia (CMML) is a clonal hematologic malignancy at the interface between myelodysplastic syndromes and myeloproliferative neoplasms. It is characterized by considerable biological and clinical heterogeneity, leading to outcomes
F. Onida, G. Albrizio, I. Casetti
doaj   +3 more sources

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation

open access: yesHematology
Background: Chronic myelomonocytic leukemia is a clonal hematological disorder with an inherent risk of transformation to acute myeloid leukemia.
Emiko Kashima   +8 more
doaj   +2 more sources

Pleural Effusion in Chronic Myelomonocytic Leukemia

open access: yesActa Haematologica, 1998
Pleural effusion in 4 patients with chronic myelomonocytic leukemia (CMML) is described in this report. According to the literature, pleural effusion in CMML is a poorly understood and rare occurrence. Two of our patients presented with pleural effusion as an initial symptom while the other 2 developed it during the course of the disease.
Bourantas, K. L.   +4 more
openaire   +4 more sources

Chronic myelomonocytic leukemia primarily presenting as life‐threatening pericardial effusion, Eldoret, Kenya: A case report

open access: yesClinical Case Reports
Key Clinical Message Chronic myelomonocytic leukemia, a rare case of hematological malignancy mainly affects the elderly and may present with life threatening pericardial effusion as an initial manifestation.
Victor M. Wauye   +4 more
doaj   +2 more sources

Chronic Myelomonocytic Leukemia: Hematopathology Perspective [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2021
Our understanding of chronic myelomonocytic leukemia (CMML) has evolved tremendously over the past decade. Large-scale sequencing studies have led to increased insight into the genomic landscape of CMML and clinical implications of these changes. This in
Siba El Hussein   +4 more
doaj   +4 more sources

Genomic determinants of chronic myelomonocytic leukemia

open access: yesLeukemia, 2017
The biology, clinical phenotype and progression rate of chronic myelomonocytic leukemia (CMML) are highly variable due to diverse initiating and secondary clonal genetic events. To determine the effects of molecular features including clonal hierarchy in CMML, we studied whole-exome and targeted next-generation sequencing data from 150 patients with ...
B J, Patel   +20 more
openaire   +4 more sources

Paraneoplastic Autoimmunity Associated with Testicular Myeloid Sarcoma and Chronic Myelomonocytic Leukemia [PDF]

open access: yesCase Reports in Hematology, 2013
Myeloid sarcomas are rare extramedullary solid tumors composed of immature myeloid cells. The clinical presentations of these malignant neoplasms are highly variable, ranging from asymptomatic to localized mass effect.
Jeffrey W. Craig, Richard J. Lin
doaj   +2 more sources

An unexpected complication of chronic myelomonocytic leukemia: severe renal failure due to malignant tubulo-interstitial cell infiltration

open access: yesInternational Journal of Nephrology and Renovascular Disease, 2015
Jerrold Spapen,1 Karel Fostier,2 Hendrik De Raeve,3 Peter Janssens,4 Herbert Spapen51Department of Internal Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 2Department of Hematology, 3Department of Pathology, 4Department of ...
Spapen J   +4 more
doaj   +1 more source

Lysozyme nephropathy in chronic myelomonocytic leukemia [PDF]

open access: yesClinical Case Reports, 2019
Lysozyme nephropathy is a frequently unrecognized cause of renal disease in chronic myelomonocytic leukemia and may serve as a novel indication for treatment in this patient population.
Ami B. Patel   +2 more
doaj   +3 more sources

A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia

open access: yesLeukemia Research Reports, 2017
Philadelphia (Ph) chromosome is a cytogenetic hallmark of chronic myeloid leukemia (CML). Most patients with CML harbor either the e13a2 or e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts.
Jinjuan Yao   +5 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy